parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in late spermatids	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 72	0.85
pathways Reactome	2 pathways; mostly vesicle traffic	1.00

No case: the score is under the bar. Receipt 9782

KIF21B in dopamine neurons, braak-0.37 (p 0.334) → -0.48 (p 0.192)receipt 9790
KIF21B in astrocytes, braak-0.31 (p 0.419) → +0.60 (p 0.090)receipt 9789

receipt 9790: KIF21B in dopamine neurons, braak

power: full sample -0.41 (p 0.095, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.42 (p 0.086, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.026, n 18). not the mix.
skeptic: leave-one-out range -0.53 to -0.33, sign flips 0; without severely affected donors -0.41 (p 0.095, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for KIF21B in dopamine neurons.

case closed: nothing better to follow up.

receipt 9789: KIF21B in astrocytes, braak

power: full sample -0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.01 (p 0.956, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.10 (p 0.690, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.13, sign flips 10; without severely affected donors -0.00 (p 0.997, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for KIF21B in astrocytes.

case closed: nothing better to follow up.

loading the receipts